Precigen Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Precigen de 55.5% y 50.9% por año respectivamente. Se prevé que el BPA crezca en un 57% al año. Se espera que la rentabilidad financiera sea de -106.8% en 3 años.

Información clave

55.5%

Tasa de crecimiento de los beneficios

57.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.0%
Tasa de crecimiento de los ingresos	50.9%
Rentabilidad financiera futura	-106.8%
Cobertura de analistas	Low
Última actualización	02 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Apr 18

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Nov 10

Precigen names Rutul Shah as chief operating officer

Sep 21

Circling Back On Precigen

Aug 23

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Aug 10

Precigen Q2 2022 Earnings Preview

Aug 07

Precigen to sell Trans Ova Genetics for $170M upfront

Jul 05

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

May 10

The Prognosis On Precigen

Jan 05

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Dec 31

Broker Revenue Forecasts For Precigen, Inc. (NASDAQ:PGEN) Are Surging Higher

Aug 12

Precigen (NASDAQ:PGEN) Is Carrying A Fair Bit Of Debt

Jul 16

Time To Worry? Analysts Are Downgrading Their Precigen, Inc. (NASDAQ:PGEN) Outlook

Mar 03

What Kind Of Investors Own Most Of Precigen, Inc. (NASDAQ:PGEN)?

Feb 12

Precigen announces positive preliminary data from early-stage PRGN-2009 cancer study

Jan 13

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:PGEN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	279	80	-97	-77	2
12/31/2025	45	-74	-90	-83	4
12/31/2024	6	-90	-72	-70	5
12/31/2023	6	-96	-68	-67	N/A
9/30/2023	7	-85	-67	-67	N/A
6/30/2023	22	-73	-75	-73	N/A
3/31/2023	23	-79	-68	-65	N/A
12/31/2022	27	-80	-70	-65	N/A
9/30/2022	29	-84	-72	-64	N/A
6/30/2022	15	-103	-66	-57	N/A
3/31/2022	16	-108	-66	-58	N/A
12/31/2021	14	-111	-63	-56	N/A
9/30/2021	30	-124	-64	-58	N/A
6/30/2021	50	-125	-64	-60	N/A
3/31/2021	77	-110	-71	-66	N/A
12/31/2020	32	-104	-85	-77	N/A
9/30/2020	101	-100	-103	-93	N/A
6/30/2020	96	-122	-118	-101	N/A
3/31/2020	98	-138	-150	-120	N/A
12/31/2019	91	-169	-174	-136	N/A
9/30/2019	108	-373	-186	-141	N/A
6/30/2019	122	-381	-188	-143	N/A
3/31/2019	134	-414	-180	-138	N/A
12/31/2018	151	-375	-166	-124	N/A
9/30/2018	194	-196	-165	-121	N/A
6/30/2018	208	-179	-164	-114	N/A
3/31/2018	217	-132	-174	-109	N/A
12/31/2017	219	-71	-165	-104	N/A
9/30/2017	200	-134	N/A	-94	N/A
6/30/2017	203	-123	N/A	-88	N/A
3/31/2017	201	-154	N/A	-77	N/A
12/31/2016	191	-187	N/A	-49	N/A
9/30/2016	186	-175	N/A	-19	N/A
6/30/2016	191	-184	N/A	49	N/A
3/31/2016	183	-176	N/A	45	N/A
12/31/2015	174	-84	N/A	36	N/A
9/30/2015	163	-33	N/A	14	N/A
6/30/2015	131	-47	N/A	-45	N/A
3/31/2015	98	-59	N/A	-42	N/A
12/31/2014	72	-82	N/A	-20	N/A
9/30/2014	48	-113	N/A	-21	N/A
6/30/2014	33	-52	N/A	-30	N/A
3/31/2014	28	-11	N/A	-30	N/A
12/31/2013	24	-57	N/A	-54	N/A
9/30/2013	23	-82	N/A	-56	N/A
6/30/2013	20	-116	N/A	-55	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PGEN sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que PGEN sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que PGEN sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (50.9% al año) de PGEN crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (50.9% al año) de PGEN crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: PGEN se prevé que no sea rentable en 3 años.

Precigen Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased to US$14.50

Consensus revenue estimates fall by 66%

Price target decreased to US$12.00

Recent updates

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy

President exercised options and sold US$575k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Precigen, Inc. to Report Q4, 2023 Results on Mar 19, 2024

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Precigen: RRP Targeting With AdenoVerse Technology Platform

Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Independent Director recently sold US$136k worth of stock

Forecast to breakeven in 2026

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Independent Director recently bought US$688k worth of stock

Consensus revenue estimates decrease by 12%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

President exercised options and sold US$58k worth of stock

Precigen, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Precigen, Inc. Receives Breakthrough Therapy Designation for PRGN- 2012 Adenoverse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers

Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer

Things Look Grim For Precigen, Inc. (NASDAQ:PGEN) After Today's Downgrade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen, Inc. to Report Q1, 2023 Results on May 10, 2023

Some Shareholders Feeling Restless Over Precigen, Inc.'s (NASDAQ:PGEN) P/S Ratio

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Precigen, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Precigen, Inc. Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

Insufficient new directors

Price target increased to US$14.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Precigen, Inc. Appoints Rutul R. Shah as Chief Operating Officer, Effective October 1, 2022

Precigen names Rutul Shah as chief operating officer

Chief Financial Officer recently bought US$51k worth of stock

Circling Back On Precigen

Independent Director recently sold US$115k worth of stock

Consensus revenue estimates fall by 66%

Independent Director notifies of intention to sell stock

Price target decreased to US$12.00

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Precigen Q2 2022 Earnings Preview

Price target increased to US$13.75

Precigen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

URUS Group LP agreed to acquire Trans Ova Genetics LC from Precigen, Inc. (NasdaqGS:PGEN) for $180 million.

Precigen to sell Trans Ova Genetics for $170M upfront

President exercised options and sold US$211k worth of stock

Consensus revenue estimates increase by 21%

Precigen, Inc. (NASDAQ:PGEN) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022

Would Precigen (NASDAQ:PGEN) Be Better Off With Less Debt?

Precigen, Inc. Announces Impairment of Goodwill for Three Months Ended March 31, 2022

Precigen, Inc. to Report Q1, 2022 Results on May 09, 2022

Precigen, Inc., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Precigen, Inc. Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Consensus estimates of losses per share improve by 14%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Precigen, Inc. to Report Q4, 2021 Results on Mar 01, 2022

The Prognosis On Precigen

Is Precigen (NASDAQ:PGEN) Using Too Much Debt?

Precigen, Inc Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia

Insufficient new directors